XFOR
X4 Pharmaceuticals, Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
X4 Pharmaceuticals has 1 disclosed supplier and 3 disclosed customers in SEC filings.
—
SentenceIn July 2014, we entered into a license agreement (the "Genzyme Agreement") with Genzyme Corporation ("Genzyme"), a wholly owned subsidiary of Sanofi, pursuant to which we were granted an exclusive license to certain patent applications and other intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds, including but not limited to, mavorixafor.
XFOR 10-Kaccession 0001501697-26-000018
SentenceWe also have a license agreement with Abbisko Therapeutics Co. Ltd. ("Abbisko"), which granted Abbisko the exclusive right to perform regulatory activities on, manufacture and distribute mavorixafor in mainland China, Taiwan, Hong Kong and Macau.
XFOR 10-Kaccession 0001501697-26-000018
SentenceO n January 13, 2025, we announced a License and Supply Agreement (the "Norgine Agreement") with Norgine Pharma UK ("Norgine"), pursuant to which Norgine was granted an exclusive license to distribute, market and sell our drug product for all indications in the European Economic Area, Switzerland, the United Kingdom, Australia, and New Zealand.
XFOR 10-Kaccession 0001501697-26-000018
SentenceIn February 2025, we announced that we had entered into an agreement with Taiba Middle East Fz LLC ("taiba rare") to distribute and commercialize XOLREMDI for the treatment of WHIM syndrome in select Middle East and North African ("MENA") countries.
XFOR 10-Kaccession 0001501697-26-000018
X4 Pharmaceuticals, Inc
3.33
Largest filed tie
—
Expected move
No implied move.